

EAST Search History

L10	3	"20050100552"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2008/01/26 13:36
L11	4	laminin adj selective	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2008/01/26 13:36
L12	13	laminin adj antagonist	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2008/01/26 13:36
L13	28	"5491073"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2008/01/26 13:36
L14	8	"6071520"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2008/01/26 13:36
S1	3	laminin adj selective	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/12/19 14:22
S2	12	laminin adj antagonist	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2007/08/28 17:11
S3	3	"2004224891"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2007/08/28 17:11
S4	2	"20040224891"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2007/08/28 17:13
S5	4	"6627403"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2007/08/28 17:14

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	4	laminin adj selective	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2008/01/26 13:36
L2	13	laminin adj antagonist	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2008/01/26 13:36
L3	3	"2004224891"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2008/01/26 13:36
L4	2	"20040224891"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2008/01/26 13:36
L5	5	"6627403"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2008/01/26 13:36
L6	12	"6294344"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2008/01/26 13:36
L7	4	laminin adj selective	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2008/01/26 13:36
L8	13	laminin adj antagonist	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2008/01/26 13:36
L9	6	"2005100552"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2008/01/26 13:36

EAST Search History

S6	9	"6294344"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2007/08/28 17:14
S7	4	laminin adj selective	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2007/08/28 17:15
S8	13	laminin adj antagonist	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2007/08/28 17:19
S9	6	"2005100552"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2007/08/28 17:19
S10	3	"20050100552"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2007/08/29 13:48
S11	4	laminin adj selective	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2007/08/28 17:26
S12	13	laminin adj antagonist	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2007/08/28 17:26
S13	27	"5491073"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2007/08/29 13:49
S14	8	"6071520"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2007/08/29 13:49

10/797,626

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptatsh1654

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	4	AUG 13	CA/CAPplus enhanced with additional kind codes for granted patents
NEWS	5	AUG 20	CA/CAPplus enhanced with CAS indexing in pre-1907 records
NEWS	6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	7	AUG 27	USPATOLD now available on STN
NEWS	8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	10	SEP 13	FORIS renamed to SOFIS
NEWS	11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	12	SEP 17	CA/CAPplus enhanced with printed CA page images from 1967-1998
NEWS	13	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS	14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	15	OCT 02	CA/CAPplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	16	OCT 19	BEILSTEIN updated with new compounds
NEWS	17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	18	NOV 19	WPIX enhanced with XML display format
NEWS	19	NOV 30	ICSD reloaded with enhancements
NEWS	20	DEC 04	LINPADOCDB now available on STN
NEWS	21	DEC 14	BEILSTEIN pricing structure to change
NEWS	22	DEC 17	USPATOLD added to additional database clusters
NEWS	23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS	24	DEC 17	DGENE now includes more than 10 million sequences
NEWS	25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS	26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS	27	DEC 17	CA/CAPplus enhanced with new custom IPC display formats
NEWS	28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS	29	JAN 02	STN pricing information for 2008 now available
NEWS	30	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),

10/797,626

AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:37:46 ON 26 JAN 2008

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.63

0.63

FILE 'REGISTRY' ENTERED AT 13:39:26 ON 26 JAN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 JAN 2008 HIGHEST RN 1000843-54-8

DICTIONARY FILE UPDATES: 25 JAN 2008 HIGHEST RN 1000843-54-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> S STQNASLLSLTVC/SQEP

1 STQNASLLSLTVC/SQEP

328905 SQL=13

L1

1 STQNASLLSLTVC/SQEP

(STQNASLLSLTVC/SQEP AND SQL=13)

=> S KGGCSTQNAQLLSLIVGKA/SQEP

1 KGGCSTQNAQLLSLIVGKA/SQEP

1516407 SQL=19

L2

1 KGGCSTQNAQLLSLIVGKA/SQEP

10/797,626

(KGGCSTQNAQLLSLIVGKA/SQEP AND SQL=19)

=> S KGGSTQNAQLLSLIVGKA/SQEP

1 KGGSTQNAQLLSLIVGKA/SQEP

182796 SQL=18

L3 1 KGGSTQNAQLLSLIVGKA/SQEP

(KGGSTQNAQLLSLIVGKA/SQEP AND SQL=18)

=> S STQNASLLSLTVC/SQSP

L4 1 STQNASLLSLTVC/SQSP

=> S KGGCSTQNAQLLSLIVGKA/SQSP

L5 1 KGGCSTQNAQLLSLIVGKA/SQSP

=> S KGGSTQNAQLLSLIVGKA/SQSP

L6 1 KGGSTQNAQLLSLIVGKA/SQSP

=> FIL HCAP

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

116.62

117.25

FILE 'HCAPLUS' ENTERED AT 13:43:38 ON 26 JAN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Jan 2008 VOL 148 ISS 5

FILE LAST UPDATED: 25 Jan 2008 (20080125/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> S L1-L6

3 L1

3 L2

3 L3

3 L4

3 L5

3 L6

L7 3 (L1 OR L2 OR L3 OR L4 OR L5 OR L6)

=> D L7 1-3 IBIB ABS HITSTR

L7 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:230430 HCAPLUS

10/797,626

DOCUMENT NUMBER: 146:288492
TITLE: inhibition of integrin-extracellular matrix interactions using agents targeted to the extracellular matrix and the integrin in prevention of angiogenesis
INVENTOR(S): Van, Epps Dennis; Freimark, Bruce; Brooks, Peter C.
PATENT ASSIGNEE(S): Cell Matrix, USA
SOURCE: PCT Int. Appl., 164pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007024921	A2	20070301	WO 2006-US32875	20060822
WO 2007024921	A3	20070614		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

US 2007048325	A1	20070301	US 2006-508754	20060822
---------------	----	----------	----------------	----------

PRIORITY APPLN. INFO.: US 2005-711060P P 20050824

AB Methods of preventing angiogenesis by preventing the interaction of integrins with the extracellular matrix (ECM) are described. The methods uses ligands that block binding of integrins and the ECM by independently interacting with the ECM and the integrins. The blocking of angiogenesis is particularly useful in cancer therapies and in methods for preventing, treating or managing angiogenic dependent conditions such as cancer. The characterization of the role of $\alpha v \beta 3$ integrins in the growth of solid tumors is described. The proliferation of $\alpha v \beta 3$ -producing tumor cells could be blocked by conditioned medium from cells not producing the integrin.

IT 771528-84-8 771528-86-0 771528-88-2



RL: PRP (Properties)

(unclaimed sequence; inhibition of integrin-extracellular matrix interactions using agents targeted to the extracellular matrix and the integrin in prevention of angiogenesis)

RN 771528-84-8 HCAPLUS

CN L-Cysteine, L-seryl-L-threonyl-L-glutaminyl-L-asparaginyL-L-alanyl-L-seryl-L-leucyl-L-leucyl-L-seryl-L-leucyl-L-threonyl-L-valyl- (CA INDEX NAME)



Absolute stereochemistry.





RN 771528-86-0 HCAPLUS

CN L-Alanine, L-lysylglycylglycyl-L-cysteinyl-L-seryl-L-threonyl-L-glutaminyl-L-asparaginyl-L-alanyl-L-glutaminyl-L-leucyl-L-leucyl-L-seryl-L-leucyl-L-isoleucyl-L-valylglycyl-L-lysyl- (CA INDEX NAME)

Absolute stereochemistry.







RN 771528-88-2 HCAPLUS

CN L-Alanine, L-lysylglycylglycyl-L-seryl-L-threonyl-L-glutaminy-L-asparaginy-L-alanyl-L-glutaminy-L-leucyl-L-leucyl-L-seryl-L-leucyl-L-isoleucyl-L-valylglycyl-L-lysyl- (CA INDEX NAME)


Absolute stereochemistry.




PAGE 1-B



PAGE 1-C



PAGE 2-A




L7 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:977981 HCAPLUS
 DOCUMENT NUMBER: 145:334147
 TITLE: Methods of inhibiting angiogenesis and tumor development
 INVENTOR(S): Brooks, Peter, C.; Akalu, Abebe; Cretu, Alexandra; Policarpio, Desiree
 PATENT ASSIGNEE(S): New York University, USA
 SOURCE: PCT Int. Appl., 153pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006098987	A2	20060921	WO 2006-US8266	20060309
WO 2006098987	A3	20070531		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
US 2006216236	A1	20060928	US 2006-371620	20060309
US 2006216237	A1	20060928	US 2006-372367	20060309
US 2006240002	A1	20061026	US 2006-371626	20060309
PRIORITY APPLN. INFO.:			US 2005-660713P	P 20050311
			US 2005-660889P	P 20050311
			US 2005-660903P	P 20050311
			US 2005-711049P	P 20050824
			US 2005-711177P	P 20050825
AB	The authors disclose methods for identifying genes and proteins modulated by antagonism of extracellular matrix (ECM) ligands that specifically interact with $\alpha v \beta 3$ integrin. The authors also disclose using the identified genes and proteins for inhibiting angiogenesis, tumor metastasis, and other tumor developmental processes, including cell migration, cell adhesion, cell proliferation, and tumor growth and for treating angiogenesis-dependent conditions. In one example, a monoclonal antibody antagonist of $\alpha v \beta 3$ is shown to modulate the expression of IGFBP-4, TSP-1, Id-1, p27KIP, and p21CIP.			
IT	771528-84-8 RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (antagonists of extracellular matrix ligand/ $\alpha v \beta 3$ integrin interaction for inhibition of tumor angiogenesis and metastasis)			
RN	771528-84-8 HCAPLUS			
CN	L-Cysteine, L-seryl-L-threonyl-L-glutaminyl-L-asparaginyll-L-alanyl-L-seryl-L-leucyl-L-leucyl-L-seryl-L-leucyl-L-threonyl-L-valyl- (CA INDEX NAME)			

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT 771528-86-0 771528-88-2



RL: PRP (Properties)



(unclaimed sequence; methods of inhibiting angiogenesis and tumor development)

RN 771528-86-0 HCAPLUS

CN L-Alanine, L-lysylglycylglycyl-L-cysteinyl-L-seryl-L-threonyl-L-glutaminyl-L-asparaginyl-L-alanyl-L-glutaminyl-L-leucyl-L-leucyl-L-seryl-L-leucyl-L-isoleucyl-L-valylglycyl-L-lysyl- (CA INDEX NAME)

Absolute stereochemistry.









RN 771528-88-2 HCAPLUS

CN L-Alanine, L-lysylglycylglycyl-L-seryl-L-threonyl-L-glutaminyll-L-asparaginyll-L-alanyl-L-glutaminyll-L-leucyl-L-leucyl-L-seryl-L-leucyl-L-isoleucyl-L-valylglycyl-L-lysyl- (CA INDEX NAME)

Absolute stereochemistry.






L7 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:857618 HCAPLUS
 DOCUMENT NUMBER: 141:325699
 TITLE: Methods for inhibiting angiogenesis, tumor growth and metastasis by using Stq-peptides as antagonists to bind to denatured laminin
 INVENTOR(S): Brooks, Peter C.; Akalu, Abebe
 PATENT ASSIGNEE(S): New York University, USA
 SOURCE: PCT Int. Appl., 50 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087734	A2	20041014	WO 2004-US9332	20040326
WO 2004087734	A3	20050728		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004224896	A1	20041111	US 2004-797626	20040309
AU 2004225986	A1	20041014	AU 2004-225986	20040326
CA 2520372	A1	20041014	CA 2004-2520372	20040326
EP 1611151	A2	20060104	EP 2004-758409	20040326
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
JP 2006524241	T	20061026	JP 2006-509356	20040326
PRIORITY APPLN. INFO.:			US 2003-458523P	P 20030328
			WO 2004-US9332	A 20040326
AB	The invention describes methods for inhibiting angiogenesis, tumor growth and metastasis in a tissue of a mammal by administering an antagonist that specifically binds to a proteolyzed or denatured laminin with substantially greater affinity than to the native form of laminin. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis or of restenosis also are described, as are methods to use such antagonists as diagnostic markers of angiogenesis in normal or diseased tissues both in vivo and ex vivo.			
IT	771528-84-8P 771528-86-0P 771528-88-2P RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (amino acid sequence; inhibiting angiogenesis, tumor growth and metastasis by using Stq-peptides as antagonists to bind to denatured laminin)			
RN	771528-84-8 HCAPLUS			
CN	L-Cysteine, L-seryl-L-threonyl-L-glutaminy-L-asparaginy-L-alanyl-L-seryl-L-leucyl-L-leucyl-L-seryl-L-leucyl-L-threonyl-L-valyl- (CA INDEX NAME)			

Absolute stereochemistry.

PAGE 1-A





PAGE 1-B





RN 771528-86-0 HCAPLUS

CN L-Alanine, L-lysylglycylglycyl-L-cysteinyl-L-seryl-L-threonyl-L-glutaminyl-L-asparaginyll-L-alanyl-L-glutaminyl-L-leucyl-L-leucyl-L-seryl-L-leucyl-L-isoleucyl-L-valylglycyl-L-lysyl- (CA INDEX NAME)

Absolute stereochemistry.







RN 771528-88-2 HCAPLUS

CN L-Alanine, L-lysylglycylglycyl-L-seryl-L-threonyl-L-glutaminyll-L-asparaginyll-L-alanyl-L-glutaminyll-L-leucyl-L-leucyl-L-seryl-L-leucyl-L-isoleucyl-L-valylglycyl-L-lysyl- (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-B



PAGE 1-C



PAGE 2-A

